Xenetic Biosciences (XBIO) Operating Expenses (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Operating Expenses came in at $1.3 million in Q1 2026, down 14.76% YoY from $1.5 million in Q1 2025, and down 5.78% on a QoQ basis from $1.4 million in Q4 2025.
Xenetic Biosciences (XBIO) Operating Expenses (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Operating Expenses data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Operating Expenses fell 14.76% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (down 13.57% YoY) and the FY2025 annual result came in at $5.8 million, down 13.33% from the prior year.
- Operating Expenses fell to $1.3 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $3.1 million in Q2 2022 to a low of $1.1 million in Q3 2024.
- A 5-year average of $1.7 million and a median of $1.7 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses surged 119.31% — and 2023, when it sank 40.42%.
- Tracing XBIO's Operating Expenses over 5 years: stood at $2.1 million in 2022, then retreated by 5.98% to $1.9 million in 2023, then fell by 9.32% to $1.7 million in 2024, then declined by 20.52% to $1.4 million in 2025, then dropped by 5.78% to $1.3 million in 2026.
- The last three Operating Expenses figures came in at $1.3 million (Q1 2026), $1.4 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 541.02 Mn |
| 10 | Xenetic Biosciences | 8.28 Mn | 1.81 Mn | - | 1.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.63 Mn |
| Mar 31, 2026 | 1.31 Mn |
| Dec 31, 2025 | 1.39 Mn |
| Sep 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Mar 31, 2025 | 1.54 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Sep 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 2.06 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 1.93 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 1.85 Mn |
| Mar 31, 2023 | 1.52 Mn |
| Dec 31, 2022 | 2.05 Mn |
| Sep 30, 2022 | 1.26 Mn |
| Jun 30, 2022 | 3.10 Mn |
| Mar 31, 2022 | 2.01 Mn |
| Dec 31, 2021 | 2.21 Mn |
| Sep 30, 2021 | 1.73 Mn |